Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.
De La Serna J, Sanz J, Bermúdez A, Cabrero M, Serrano D, Vallejo C, Gómez V, Moraleda JM, Perez SG, Caballero MD, Conde E, Lahuerta JJ, Sanz G. De La Serna J, et al. Among authors: cabrero m. Bone Marrow Transplant. 2016 Jul;51(7):961-6. doi: 10.1038/bmt.2016.42. Epub 2016 Mar 7. Bone Marrow Transplant. 2016. PMID: 26950372 Clinical Trial.
The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
Perez-Simón JA, Martino R, Parody R, Cabrero M, Lopez-Corral L, Valcarcel D, Martinez C, Solano C, Vazquez L, Márquez-Malaver FJ, Sierra J, Caballero D. Perez-Simón JA, et al. Among authors: cabrero m. Haematologica. 2013 Apr;98(4):526-32. doi: 10.3324/haematol.2012.065599. Epub 2012 Oct 12. Haematologica. 2013. PMID: 23065527 Free PMC article. Clinical Trial.
The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial).
Montesinos P, Cabrero M, Valcárcel D, Rovira M, García-Marco JA, Loscertales J, Moreno C, Duarte R, Terol MJ, Villamor N, Abrisqueta P, Caballero D, Sanz J, Delgado J. Montesinos P, et al. Among authors: cabrero m. Bone Marrow Transplant. 2016 Oct;51(10):1404-1407. doi: 10.1038/bmt.2016.145. Epub 2016 May 23. Bone Marrow Transplant. 2016. PMID: 27214073 Clinical Trial. No abstract available.
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Kekre N, Marquez-Malaver FJ, Cabrero M, Piñana J, Esquirol A, Soiffer RJ, Caballero D, Terol MJ, Martino R, Antin JH, Lopez-Corral L, Solano C, Armand P, Pérez-Simon JA. Kekre N, et al. Among authors: cabrero m. Biol Blood Marrow Transplant. 2016 Oct;22(10):1808-1815. doi: 10.1016/j.bbmt.2016.07.006. Epub 2016 Jul 25. Biol Blood Marrow Transplant. 2016. PMID: 27470290 Free article.
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
Cabrero M, Martin A, Briones J, Gayoso J, Jarque I, López J, Grande C, Heras I, Arranz R, Bernal T, Perez-Lopez E, López-Godino O, Conde E, Caballero D. Cabrero M, et al. Biol Blood Marrow Transplant. 2017 Jan;23(1):53-59. doi: 10.1016/j.bbmt.2016.10.003. Epub 2016 Oct 19. Biol Blood Marrow Transplant. 2017. PMID: 27771496 Free article. Clinical Trial.
Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation.
Rivera D, Bastida JM, Lopez-Corral L, Sanchez-Guijo F, Cabrero M, Martin A, Perez E, Lopez-Parra M, Avendaño A, Veiga A, Baile M, Arratibel N, Carrillo J, Vazquez L, Caballero MD, Gonzalez-Porras JR. Rivera D, et al. Among authors: cabrero m. Bone Marrow Transplant. 2019 May;54(5):757-761. doi: 10.1038/s41409-018-0368-1. Epub 2018 Oct 24. Bone Marrow Transplant. 2019. PMID: 30356164 Clinical Trial. No abstract available.
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.
Caballero JC, Sánchez Barba M, Hernández Sánchez JM, Such E, Janusz K, Sanz G, Cabrero M, Chillón C, Cervera J, Hurtado AM, Jerez A, Calderón Cabrera C, Valcárcel D, Lumbreras E, Abáigar M, López Cadenas F, Hernández Rivas JM, Del Cañizo MC, Díez Campelo M. Caballero JC, et al. Among authors: cabrero m. Ann Hematol. 2019 Sep;98(9):2151-2162. doi: 10.1007/s00277-019-03751-6. Epub 2019 Jul 16. Ann Hematol. 2019. PMID: 31312927
Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors.
Montoro J, Chorão P, Bento L, Cabrero M, Martín C, Novelli S, Cadenas IG, Gutiérrez G, López-Godino O, Ferrá C, Bastos-Oreiro M, Pérez A, Parody R, Pérez Simón JA, Yañez L, Sánchez A, Zanabili J, Varela MR, Córdoba R, Zudaire T, Jiménez-Ubieto A, Sanz J, Sureda A, Caballero D, Piñana JL; GETH and GELTAMO Group. Montoro J, et al. Among authors: cabrero m. Bone Marrow Transplant. 2021 Apr;56(4):992-996. doi: 10.1038/s41409-020-01161-1. Epub 2020 Dec 12. Bone Marrow Transplant. 2021. PMID: 33311593 No abstract available.
Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study.
Bento L, Gutiérrez A, Novelli S, Montoro J, Piñana JL, López-Corral L, Cabrero M, Martín-Sancho A, Gutiérrez-García G, Ortiz-Moscovich M, Bastos-Oreiro M, Dorado N, Pérez A, Hernani R, Ferrà C, Parody R, García-Cadenas I, Herrera P, Rodríguez G, Rodríguez N, Martín C, Yáñez L, Zanabili J, Varela MR, López-Godino O, Heras I, Español I, Martínez C, Pérez-Simón JA, Solano C, Sureda A, Sierra J, Sampol A, Caballero D; Grupo Español de Trasplante Hematopoyético (GETH) and Grupo Español de Linfoma y Trasplante Autólogo (GELTAMO). Bento L, et al. Among authors: cabrero m. Bone Marrow Transplant. 2021 Aug;56(8):1919-1928. doi: 10.1038/s41409-021-01264-3. Epub 2021 Mar 25. Bone Marrow Transplant. 2021. PMID: 33767400
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
Cabrero M, López-Corral L, Jarque I, de la Cruz-Vicente F, Pérez-López E, Valcárcel D, Sanz J, Espigado I, Ortí G, Martín-Calvo C, de la Serna J, Caballero D; Grupo Español de Trasplante Hematopoyético (GETH) and Grupo Español de Linfomas y Trasplante Autólogo (GELTAMO). Cabrero M, et al. Bone Marrow Transplant. 2024 Mar;59(3):359-365. doi: 10.1038/s41409-023-02171-5. Epub 2024 Jan 2. Bone Marrow Transplant. 2024. PMID: 38167647 Clinical Trial.
41 results